Royalty Report: Drugs, Disease, Therapeutic – Collection: 209505


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 8


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8

Primary Industries

  • Drugs
  • Disease
  • Therapeutic
  • Medical
  • Device
  • Diagnostic
  • HIV / AIDs
  • Delivery
  • Biotechnology
  • Ophthalmological

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 209505

License Grant
Licensor grants an exclusive license under the Licensed Patents and Know How to make, have made, use, sell, offer to sell, import and export the Product within the Field throughout the Territory, with a right to sublicense to its Affiliates or to any other Person.
License Property
The compound NX1838, is an oligonucleotide angiogenesis inhibitor that binds to vascular endothelial growth factor (VEGF165).

VEGF is known to play a role in the development of both ophthalmic diseases.

The Product shall mean any pharmaceutical composition containing NX1838 in any formulation, dosage concentration or volume, together with all label expansions, line extensions and improvements thereon, which may be included in any supplement, modification or addition to the filings for Regulatory Approval of the foregoing compound.

Field of Use
The Field shall mean the prevention and treatment of all human and other animal diseases and conditions, and expressly excluding in vivo and in vitro diagnostic applications.

NX 1838 has the potential to be a breakthrough drug for the treatment of neovascular AMD.

AMD is the leading cause of vision loss and blindness in people aged 65 and older. The disease is characterized by the growth of blood vessels into the center of the retina. Over time, the leakage from these small blood vessels causes the formation of scar tissue on the retina. A patient’s central vision gradually deteriorates as the disease destroys the retina, ultimately resulting in irreversible blindness. The two common types of AMD are atrophic ('dry') and neovascular ('wet'). Wet macular degeneration accounts for approximately 10 percent of all cases but is a more serious threat to complete vision loss than the dry form.

IPSCIO Record ID: 344589

License Grant
Licensor grants an exclusive, worldwide license and sublicense, with the right to sublicense, under the Licensor Technology, based on existing agreements in place, to research, develop, use, have used, make, have made, import or have imported, export or have exported, offer for sale or have offered for sale, and/or sell or have sold Licensed Products in the Field.
License Property
The various patents relate to Treating Ocular Disorders and include but are not limited to
Susceptibility Genes for Age Related Maculopathy (ARM) on Chromosome 10q26;
Variants in Complement Regulatory Genes Predict Age-Related Macular Degeneration;
Methods for Diagnosing, Preventing or Treating Drusen Formation;
Diagnostics and Therapeutics for Aortic Aneurysm;
Diagnostics and Therapeutics for Ocular disorders;
Diagnostics and Therapeutics for Drusen Associated Ocular Disorders;
Diagnostics and therapeutics for macular degeneration-related disorders;
Factor H-Based Diagnostics;
Methods and Compositions for Treating Ocular Disorders;
Methods and Reagents for Treatment and Diagnosis of Vascular Disorders and Age-Related Macular Degeneration;
Association of SNPs with Complement Related Diseases;
Genetic Variants Increase the Risk of Age-Related Macular Degeneration;
Diagnosis and Therapeutic Target for Macular Degeneration;
Methods and Compositions for Prognosing, Detecting, and Treating Age-Related Macular Degeneration;
Method Evolved · for Recognition and Testing of Age Related Macular Degeneration (Mert-Armd);
Method of Detecting Ocular Diseases and Pathologic Conditions and Treatment of Same; and,
Genes Associated with Macular Degeneration.
Field of Use
Licensee has the rights to develop and commercialize diagnostic tests to predict genetic predisposition to late stage age-related macular degeneration (AMD).

AMD is an insidious progressive eye disorder that starts with relatively harmless tiny yellow deposits on the retina (the light sensitive tissue in the eye) and increases in prevalence and severity with age. The end stage of this condition, called neovascular or 'wet AMD', develops in 10 to 20% of all cases, causes profound loss of central vision and is the leading source of legal blindness in people over age 50 in the developed world. It is caused by abnormal growth of fragile and leaky blood vessels (choroidal neovascularization or 'CNV') in the macula (a small area where vision is keenest at the center of the retina) in response to chronic inflammatory stress.

Field shall mean any and all diagnostic, which includes prognostic, uses for research, laboratory developed tests or in vitro diagnostic tests markets, for use with any and all types of technology platforms.

IPSCIO Record ID: 249885

License Grant
The Parties announced a new collaboration to develop IONIS-FB-LRx for the treatment of complement-mediated diseases. This collaboration will leverage the companys leadership in RNA-targeted therapeutics to develop IONIS-FB-LRx targeting Factor B (FB) for a broad range of diseases. The first indication the two companies will pursue is the treatment of patients with Geographic Atrophy (GA), the advanced stage of dry age-related macular degeneration (AMD). A Phase 2 study in patients with GA is planned to begin in early 2019.
License Property
IONIS-FB-LRx, an antisense drug using the companys advanced LIgand Conjugated Antisense (LICA) technology, reduces the production of FB, a key protein in the complement innate immune system. FB is predominately produced in the liver and circulates throughout the vascular system, including vessels in the eye and kidney. This complement protein plays a pivotal role in an innate immunogenic cascade that, when overactivated, has been associated with the development of several complement-mediated diseases, including dry AMD.

AMD means Age-related macular degeneration.

Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 273442

License Grant
Licensor grants a non-exclusive license under the Licensed Patent Rights to make, have made, use and sell EYE001 worldwide. The license is sublicensable.
License Property
EYE001NX1838 is a non-antisense therapeutic product, or any product containing NX1838 non-antisense therapeutic product for the treatment of ophthalmic conditions.

EYE 001, NX 1838) is a pegylated oligonucleotide aptamer that binds to and inhibits extracellular VEGF 165, thereby inhibiting angiogenesis.

Field of Use
The field of use is for the treatment of the wet form of age-related macular degeneration.

IPSCIO Record ID: 234135

License Grant
Prior to entering into the New Collaboration Agreement, the Company held the worldwide license from Licensor for the use of Licensor’s proprietary insert technology for the treatment of all ocular diseases other than uveitis. The New Collaboration Agreement expands the license to include uveitis, including NIPU, in Europe, the Middle East and Africa and allows the Company to also pursue an indication for posterior uveitis for ILUVIEN in those territories.  The New Collaboration Agreement converts the Company’s obligation to share 20% of its net profits to a royalty payable on global net revenues of ILUVIEN.
License Property
ILUVIEN is indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).

Uveitis is an inflammatory disease of the uveal tract, which is comprised of the iris, ciliary body and choroid, that can lead to severe vision loss and blindness.

Diabetic Macular Edema (DME) is an accumulation of fluid in the macula—part of the retina that controls our most detailed vision abilities—due to leaking blood vessels. In order to develop DME, you must first have diabetic retinopathy. Diabetic retinopathy is a disease that damages the blood vessels in the retina, resulting in vision impairment.

Field of Use
This agreement pertains to the drug industry relating for the treatment of vision impairment.

IPSCIO Record ID: 613

License Grant
The Licensor hereby grants to the Licensee, a sole and exclusive irrevocable right and license, including the right to sublicense, under and to Intellectual Property to make, have made, use, sell, offer for sale, import or otherwise commercialize Licensed Products in the Critical Field of Use, and to Jointly-Owned Intellectual Property to make, have made, use, sell, offer for sale, import or otherwise commercialize Topical siRNA and Licensed Products in the Critical Field of Use and the Non-Critical Field of Use. Scope of Collaboration. The Parties shall work together to research and develop the Topical siRNA.
License Property
Licensor is a RNAi delivery technology company and the Licensee has proprietary technology and expertise in the area of ophthalmic pharmaceutical clinical development.
Field of Use
The License and Collaboration agreement is in the field of the treatment of ophthalmic diseases characterized by excessive or unwanted neovasculature, angiogenesis or leakage.

Critical Field of Use means the treatment of ophthalmic diseases characterized by excessive or unwanted neovasculature, angiogenesis or leakage such as but not limited to Wet AMD, diabetic retinopathy, diabetic macular edema, retinal vein occlusion, neovascular glaucoma, retinopathy of prematurity, Von Hippel Angioma, von-hippel landau, Corneal Neovascularization, Rubeosis, Pterygium or Iris Neovascularization as well as, dry AMD, drusen and uveitis.

IPSCIO Record ID: 258420

License Grant
The parties entered into a collaboration to develop and commercialize gene therapy treatments for Inherited Retinal diseases (IRDs).  The Licensee will receive worldwide exclusive rights to commercialize product candidates for achromatopsia (ACHM) caused by mutations in either CNGB3 or CNGA3, X-linked retinitis pigmentosa (XLRP) and options to additional IRD programs.
License Property
Under the agreement, the two companies will collaborate in the clinical development of Licensors leading IRD pipeline, including product candidates for achromatopsia (ACHM) caused by mutations in either CNGB3 or CNGA3 and X-linked retinitis pigmentosa (XLRP). In addition, the parties are entering into a research collaboration covering Licensor’s pipeline of pre-clinical programs for IRDs. The two companies are also entering into a research collaboration to further develop AAV manufacturing technology as well as clinical and commercial manufacturing supply agreements for the clinical and research programs.

X-linked retinitis pigmentosa (XLRP) is and inherited condition caused by mutations in the RPGR gene. XLRP causes progressive vision loss in boys and young men. The condition begins with night blindness and is followed by progressive constriction of the field of vision. XLRP often results in total blindness and there is no specific treatment for this condition.

Field of Use
Achromatopsia (ACHM) is an inherited retinal disease that prevents cone photoreceptors from functioning. Patients are legally blind from birth and usually suffer from severely reduced visual acuity of 20/200 or worse; a disabling sensitivity to light, or photophobia; total color blindness; and involuntary back and forth eye movements, or nystagmus. There are currently no approved treatments for achromatopsia.

AAV-CNGB3 and AAV-CNGA3, gene therapy candidates designed to restore cone function, are delivered via subretinal injection to the area of the eye where most of the cones in the retina are located. AAV-CNGB3 was granted orphan drug designation (ODD), rare pediatric disease and Fast Track designations by the U.S. Food and Drug Administration (FDA), and orphan medicinal product and PRIME designations by the European Medicines Agency (EMA) for the treatment of achromatopsia caused by mutations in the CNGB3 gene. A Phase 1/2 clinical trial of AAV-CNGB3 in both adult and pediatric patients is underway.

X-linked retinitis pigmentosa (XLRP) represent some of the most severe forms of RP, resulting in early onset in childhood and rapid progression to blindness by the time patients reach 20 to 30 years old. In XLRP, both rods and cones function poorly, leading to degeneration of the retina and total blindness. There are currently no approved treatments for XLRP.

AAV-RGPR is designed to treat the most common form of XLRP caused by mutations in the RPGR gene. Both rod and cone photoreceptors require RPGR to function. AAV-RPGR has received Fast Track designation and ODD from the FDA and orphan medicinal product designation from the EMA. A Phase 1/2 clinical trial of AAV-RPGR in adult and pediatric patients is underway.

This strategic collaboration agreement is related to development and commercialization of gene therapies for the treatment of inherited retinal diseases (IRDs).  IRDs are a group of rare eye conditions caused by an inherited gene mutation that are often characterized by progressive retinal degeneration which leads to severe vision impairment, loss or blindness.

IPSCIO Record ID: 197910

License Grant
The Licensor announced an amendment of its exclusive license and collaboration agreement with Licensee that grants Licensee rights to Licensor’s Durasertâ„¢ three-year treatment for posterior segment uveitis (Durasert) in Europe, the Middle East and Africa (EMEA).  With this license, Licensee plans to pursue a secondary indication for ILUVIEN for posterior segment uveitis in EMEA, which could accelerate the uveitis indication approval as well as commercialization. Licensor retains commercialization rights for posterior segment uveitis in all other countries, including the United States. The amended agreement also modifies the companies’ existing global licensing agreement for ILUVIEN for the treatment of diabetic macular edema (DME).
License Property
ILUVIEN is for the treatment of posterior segment uveitis.   ILUVIEN®, a micro-insert for diabetic macular edema.

Posterior segment uveitis is a chronic, non-infectious inflammatory disease affecting the posterior segment of the eye, often involving the retina, which is believed to be a leading cause of blindness in the developed and developing countries. It affects people of all ages, producing swelling and destroying eye tissues, which can lead to severe vision loss and blindness. In the U.S. and EU, posterior uveitis affects approximately 200,000 people, annually. Today, patients with posterior uveitis are typically treated with systemic steroids, but over time frequently develop serious side effects that can limit effective dosing. Patients then often progress to steroid-sparing therapy with systemic immune suppressants or biologics, which themselves can have severe side effects including an increased risk of cancer.

Field of Use
This agreement pertains to the drug industry relating to products for treating eye diseases.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.